Competitive edge
Highly potent and selective BACE inhibitors with
exellent pharmacokinetic properties have been identified.
These inhibitors demonstrate potent in vivo efficacy based on biomarkers in a preclinical test model. BACE inhibitors have the potential to become the
primary therapy to block the development of
Alzheimer's disease. |
